FDA NEWS RELEASE
January 18, 2010
Please forward to your members.
For Immediate Release:
FDA Warns Consumers about Counterfeit Alli
The counterfeit products contain controlled substance sibutramine
The U.S. Food and Drug Administration is today warning consumers about a counterfeit and potentially harmful version of Alli 60 mg capsules (120 count refill kit).
Preliminary laboratory tests conducted by GlaxoSmithKline (GSK)—the maker of the FDA approved over-the-counter weight-loss product— revealed that the counterfeit version did not contain orlistat, the active ingredient in its product. Instead, the counterfeit product contained the controlled substance sibutramine. Sibutramine is a drug that should not be used in certain patient populations or without physician oversight. Sibutramine can also interact in a harmful way with other medications the consumer may be taking.
To read the entire news release with photos, please follow the following link…
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm197857.htm
Carlos M. Aquino
Compliance Consultant
PharmaDiversion LLC
1167 West Baltimore Pike, Suite 231
Media PA 19063
PHONE: (610) 487-4663
Email:
carlos@pharmadiversion.com
Website: www.pharmadiversion.com